liriopesides B

antineoplastic from Liriope spicata; structure in first source

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

1.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2020 - "Therefore, liriopesides B may be considered as a candidate drug against ovarian cancer." 09/01/2017 - "Liriopesides B exhibited potential anticancer activity against human ovarian cancer A2780 cells." 09/01/2017 - "Liriopesides B inhibited cell growth and decreased CA125 level in human ovarian cancer A2780 cells." 01/01/2020 - "Liriopesides B from Liriope spicata var. prolifera inhibits metastasis and induces apoptosis in A2780 human ovarian cancer cells." 09/01/2017 - "To study the effect of liriopesides B on cell growth curve, cell doubling time, the activity of tumour marker CA125 and alkaline phosphatase (AKP) in human ovarian cancer A2780 cells. "
2.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2024 - "This study investigated the synergistic effects of the combination of liriopesides B (LirB) from Liriope spicata var. prolifera and GEM on human pancreatic cancer cells. " 01/01/2024 - "Inhibitory effect of liriopesides B in combination with gemcitabine on human pancreatic cancer cells."
3.	Neoplasm Metastasis (Metastasis) 01/01/2020 - "Liriopesides B from Liriope spicata var. prolifera inhibits metastasis and induces apoptosis in A2780 human ovarian cancer cells."
4.	Lung Neoplasms (Lung Cancer) 09/01/2020 - "Liriopesides B induces apoptosis and cell cycle arrest in human non‑small cell lung cancer cells."